MARKET

NVIV

NVIV

Invivo Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.540
+0.020
+0.44%
After Hours: 4.530 -0.01 -0.22% 16:27 05/20 EDT
OPEN
4.473
PREV CLOSE
4.520
HIGH
4.565
LOW
4.473
VOLUME
3.68K
TURNOVER
0
52 WEEK HIGH
23.19
52 WEEK LOW
3.500
MARKET CAP
6.32M
P/E (TTM)
-0.6067
1D
5D
1M
3M
1Y
5Y
OCN, NVIV and XBIT among mid-day movers
Gainers: Statera Biopharma (STAB) +132%. SQZ Biotechnologies (SQZ) +35%. RCM Technologies (RCMT) +24%. Integrated Media Technology (IMTE) +21%. Ocwen Financial (OCN) +21%. Pitney Bowes (PBI) +20%. Allego (ALLG) +18%. PTC (PTC) +16%. LSI
Seekingalpha · 04/28 16:31
Nutex, Repligen top healthcare gainers; Molecular Partners, Agile lead losers' pack
Gainers: Nutex Health (NUTX) +24%. Repligen (RGEN) +14%. Zentalis Pharmaceuticals (ZNTL) +14%. Alkermes (ALKS) +12%. Clever Leaves (CLVR) +8%. Losers: Molecular Partners (MOLN) -37%. Agile Therapeutics (AGRX) -28%. Immunome (IMNM) -10%. PetVivo (PETV) -4%....
Seekingalpha · 04/27 14:01
Stocks That Hit 52-Week Lows On Monday
    On Monday, 466 companies hit new 52-week lows.
Benzinga · 04/18 15:40
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 04/18 13:18
Why Are InVivo Therapeutics Shares Trading Lower During Premarket Monday?
Benzinga · 04/18 12:54
InVivo Therapeutics stock sinks after 1-for-25 reverse stock split announced
InVivo Therapeutics Holdings Corp. said Thursday it will carry out a 1-for-25 reverse stock split, which is intended to increase the per-share trading price of its stock and fulfill the Nasdaq Capital Market's $1 minimum bid price requirement.
marketwatch.com · 04/14 20:49
InVivo Therapeutics slumps 7% on 1-for-25 reverse stock split
 InVivo Therapeutics (NASDAQ:NVIV) announces a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock.  It will be effective at 5.00 pm ET on April
Seekingalpha · 04/14 20:40
52 Biggest Movers From Friday
Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share.
Benzinga · 01/31 10:03
More
No Data
Learn about the latest financial forecast of NVIV. Analyze the recent business situations of Invivo Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

100.00%Strong Buy
0.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
EPS
Actual
Estimate
-4.32-3.24-2.16-1.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q1 2020
Institutional Holdings
Institutions: 38
Institutional Holdings: 120.90K
% Owned: 8.69%
Shares Outstanding: 1.39M
TypeInstitutionsShares
Increased
4
2.58K
New
6
514
Decreased
3
12.01K
Sold Out
5
8.63K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.36%
Healthcare Equipment & Supplies
+0.36%
Key Executives
Non-Executive Chairman/Independent Director
C. Ann Merrifield
President/Chief Executive Officer/Director
Richard Toselli
Chief Financial Officer
Richard Christopher
Independent Director
Daniel Marshak
Independent Director
Christina Morrison
Independent Director
Richard Roberts
Independent Director
Robert Rosenthal
No Data
No Data
About NVIV
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Webull offers kinds of Invivo Therapeutics Holdings Corp stock information, including NASDAQ:NVIV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVIV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVIV stock methods without spending real money on the virtual paper trading platform.